{
    "nctId": "NCT02596373",
    "briefTitle": "A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer",
    "officialTitle": "A Randomized, Open-label, Positive-controlled, Single-institutional, Phase \u2161 of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Advanced Recurrent or Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "ORR(Objective reponse rate)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent prior to study specific screening procedures;\n* \u2265 18 and \u2264 75 years of age,female;\n* Advanced recurrent or Metastatic breast cancer, comfirmed by histological analysis and/or cytology analysis. Have failed for at least two chemotherapy regimen aimed to the advanced recurrent or metastatic focus;\n* Adapted to receive chemotherapy;\n* Women diagnosed with human epidermal growth factor receptor negative(HER2-); Women diagnosed with HER2+, and unable to be treated by Anti-HER2+ targeted therapy. HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH negative for gene amplification. HER2+ is defined as +++ staining on immunohistochemistry or FISH positive for gene amplification;\n* Not suitable for endocrine theapy or tolerance to endocrine therapy;\n* Have at least one measurable site of disease according to RECIST1.1 criteria;\n* If chemotherapy regimens containing anthracycline-based drugs, duration from palindromia to this chemotherapy regimens is not less than 12 mounths;\n* ECOG performance status of 0-2, life expectancy of more than 3 mounths;\n* Cardiac function is almost normal(NYHA classification is Grade 1, LVEF\u2265 50\uff05);\n* Sexually active women of childbearing potential must use a medically acceptable form of contraception;\n* Adequate hepatic, renal and hematologic functions: leukocyte\u22653.0\u00d710\\^9/L,neutrophils\u22651.5\u00d710\\^9/L,platelets\u226575\u00d710\\^9/L, hemoglobin\u226590g/L, serum bilirubin\u22641.5\u00d7ULN, ALT\u22642.5\u00d7ULN(5\u00d7for liver metastasis),AST\u22642.5\u00d7ULN(5\u00d7for liver metastasis), creatinine clearance rate\u22641.5\u00d7ULN;\n\nExclusion Criteria:\n\n* Suffering from serious internal disease, including serious heart attack, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer;\n* Uncontrolled brain metastases;\n* Pregnant or lactating women;\n* Mitoxantrone has been used before;\n* Anthracycline-based drugs was used after relapse and metastasis;\n* The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 360 mg/m2 and 600 mg/m2, respectively;\n* Less than 4 weeks from the last chemotherapy, less than 4 weeks from the last radiotherapy, less than 2 weeks from the last endocrinotherapy; Other antineoplastic drugs need to be used in this study;\n* History of anthracycline-based drug allergy;\n* History of liposome drug allergy;\n* Uncontrolled psychosis or uncontrolled infections disease;\n* Unsuited to participate in thsi study judged by investigators;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}